TARSUS PHARMACEUTICALS, INC. Gain (Loss) on Extinguishment of Debt
TARSUS PHARMACEUTICALS, INC. (TARS) reported Gain (Loss) on Extinguishment of Debt of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-02-23
- TARSUS PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-12-31 was $0.00.
- TARSUS PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-09-30 was $0.00.
- TARSUS PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-06-30 was $0.00.
- TARSUS PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for the quarter ending 2025-03-31 was $0.00.
- TARSUS PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2025 was $0.00.
- TARSUS PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2024 was -$1.94M.
- TARSUS PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2023 was $0.00.
- TARSUS PHARMACEUTICALS, INC. gain (loss) on extinguishment of debt for fiscal 2022 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | $0.00 derived: sum of 4 quarters · filed 2026-02-23 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | $0.00 derived: sum of 4 quarters · filed 2026-02-23 |
| 2025-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | -$1.94M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | -$1.94M derived: sum of 3 quarters · filed 2026-02-23 | -$1.94M 10-K · filed 2026-02-23 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-04 | -$1.94M derived: sum of 2 quarters · filed 2025-11-04 | -$1.94M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | -$1.94M 10-Q · filed 2025-08-06 | -$1.94M 10-Q · filed 2025-08-06 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-02-25 | |||
| 2020-12-31 | $0.00 10-K · filed 2021-03-31 | |||
| 2019-12-31 | -$255.00K 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |